^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DRD3 antagonist

    Related drugs:
    1m
    Adjunct Sphenopalatine Ganglion Analgesia for Rapid Discharge (ASGARD) among emergency department patients with headache (ACTRN12626000624381)
    P=N/A, N=104, Recruiting, Eastern Health | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date • Head-to-Head
    |
    chlorpromazine
    2ms
    Application of Multimodal Intervention in the Prevention of Postoperative Nausea and Vomiting After Gynecological Laparoscopic Surgery (clinicaltrials.gov)
    P=N/A, N=212, Not yet recruiting, Sir Run Run Shaw Hospital
    New trial
    |
    dexamethasone injection
    2ms
    Pharmaco-Epigenomic response of Pimozide is mediated through miR-2909. (PubMed, Integr Biol (Camb))
    This integrative approach-combining molecular biology, gene expression profiling, and epigenetic analysis-provides new biological insight into the repurposing of psychiatric drugs for cancer therapy. Our findings highlight the therapeutic potential of targeting microRNA-epigenetic interactions and suggest a broader applicability of integrating pharmacology with systems biology to uncover unconventional roles of known drugs in cancer treatment.
    Journal
    |
    DNMT3B (DNA Methyltransferase 3 Beta) • AATF (Apoptosis Antagonizing Transcription Factor)
    3ms
    Adjunct Sphenopalatine Ganglion Analgesia for Rapid Discharge (ASGARD) among emergency department patients with headache (ACTRN12626000624381)
    P=N/A, N=104, Not yet recruiting, Eastern Health
    New trial • Head-to-Head
    |
    chlorpromazine
    3ms
    Dual action of pimozide through lysosome disruption and inhibition of STATs induces apoptosis in chronic lymphocytic leukemia (CLL). (PubMed, Blood Adv)
    Pimozide also synergizes with venetoclax to induce apoptosis in CLL cells even following IL-4/CD40L signaling. This suggests that dual targeting of lysosomal function and STAT signaling represents a promising therapeutic approach to improve venetoclax efficacy and overcome TME-mediated drug resistance in CLL.
    Journal • IO biomarker
    |
    MCL1 (Myeloid cell leukemia 1) • CD40LG (CD40 ligand) • IL4 (Interleukin 4)
    |
    Venclexta (venetoclax)
    3ms
    Amisulpride for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery (clinicaltrials.gov)
    P=N/A, N=526, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New trial
    3ms
    MainRexult: Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia (clinicaltrials.gov)
    P=N/A, N=6, Completed, The University of Hong Kong | Recruiting --> Completed | N=10 --> 6 | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial completion • Enrollment change • Trial primary completion date
    4ms
    Targeting STAT5A via CRISPR/Cas9 restores TKI sensitivity in resistant chronic myeloid leukemia cells. (PubMed, Med Oncol)
    These findings identify STAT5A as a mechanistically validated and clinically actionable target, supporting its potential for combination strategies with TKIs or STAT5 inhibitors such as pimozide...STAT5A emerges as a compelling therapeutic target, meriting further investigation in preclinical models and patient-derived samples to evaluate its translational potential. Future validation in patient-derived CD34⁺ CML models may advance STAT5A-based therapeutic design.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • JAK2 (Janus kinase 2) • CCND1 (Cyclin D1) • BCL2L1 (BCL2-like 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CD34 (CD34 molecule) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • STAT5A (Signal Transducer And Activator Of Transcription 5A) • ANXA5 (Annexin A5)
    4ms
    Efficacy and safety of amisulpride combined with ondansetron in preventing postoperative nausea and vomiting (ChiCTR2600120471)
    P=N/A, N=90, The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University
    New trial
    |
    ondansetron
    4ms
    Comparison of the efficacy of amisulpride and aprepitant for the rescue treatment of postoperative nausea and vomiting in the PACU: A randomized controlled trial (ChiCTR2600119505)
    P4, N=486, Central Hospital Affiliated to Shandong First Medical University; Central Hospital Affiliated to Shandong First Medical University
    New P4 trial
    4ms
    ENX-104-004: A Study of ENX-104 in Healthy Participants (clinicaltrials.gov)
    P1, N=12, Completed, Engrail Therapeutics INC | Recruiting --> Completed
    Trial completion
    4ms
    NOVA2: Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia (clinicaltrials.gov)
    P3, N=456, Recruiting, LB Pharmaceuticals Inc. | Not yet recruiting --> Recruiting
    Enrollment open